Gliptivil (Vildagliptin)

Gliptivil is indicated for the treatment of type 2 diabetes mellitus in adults when diet, exercise, and other oral antidiabetic agents do not provide adequate glycemic control.

• Used as monotherapy in patients who are newly diagnosed or have mild hyperglycemia.
• Combined with metformin when metformin alone is insufficient.
• Added to sulfonylureas or thiazolidinediones for patients requiring additional glucose lowering.
• May be part of a fixed‑dose combination with other oral agents (if available).
• Prescribed to improve post‑prandial glucose excursions.

The safety profile of vildagliptin, the active component of Gliptivil, includes both common and less frequent adverse events observed in clinical use.

Common

• Upper respiratory tract infection, such as nasopharyngitis or sinusitis.
• Headache, ranging from mild to moderate intensity.
• Dizziness or light‑headed feeling, especially when standing quickly.
• Nausea, occasionally accompanied by mild abdominal discomfort.
• Diarrhea, usually mild and self‑limiting.
• Fatigue or general weakness.

Serious

• Acute pancreatitis, presenting with persistent abdominal pain, nausea, and elevated pancreatic enzymes.
• Severe hypersensitivity reactions, including angioedema, skin rash, or rare Stevens‑Johnson syndrome.

When prescribing Gliptivil, clinicians should consider several precautionary measures to ensure safe use in diverse patient populations.

• Assess renal function before initiation; dose adjustment may be required in moderate to severe impairment.
• Monitor hepatic enzymes periodically, as liver disease can affect drug metabolism.
• Use with caution in elderly patients due to higher risk of hypoglycemia when combined with insulin secretagogues.
• Evaluate for a history of pancreatitis; discontinue if pancreatitis recurs.
• Consider pregnancy and lactation status; the safety profile in these groups is not well established.
• Review concomitant medications that may increase the risk of hypoglycemia.

Gliptivil can interact with other medicines; understanding which combinations to avoid or use cautiously helps maintain glycemic control and reduce adverse effects.

Avoid

• Concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole) that may increase vildagliptin exposure.
• Co‑administration with other DPP‑4 inhibitors, as additive effects are not recommended.
• Use with insulin or sulfonylureas without dose adjustment, due to heightened hypoglycemia risk.

Use with caution

• Combining with dipeptidyl peptidase‑4 substrates such as saxagliptin; monitor blood glucose closely.
• Patients receiving high‑dose thiazolidinediones; monitor for fluid retention and liver function.
• NSAIDs or aspirin may increase risk of gastrointestinal irritation when taken with metformin‑based regimens that include Gliptivil.